» Articles » PMID: 33803704

A Commentary on Realities of Developing COVID-19 Vaccines Discussed Through the Global Health Safety Perspective

Overview
Date 2021 Apr 3
PMID 33803704
Citations 4
Authors
Affiliations
Soon will be listed here.
Abstract

SARS-CoV-2 (or simply COVID-19) remains to be a global pandemic issue affecting millions, thus urging the world's scientific community to develop efficient vaccine and design adequate measures of disease control. Currently, the most economically viable solution to infections and viruses is vaccination, despite the possible concerns about side effects from implementing quickly developed vaccine. The current commentary intends to explain the health and safety related to COVID-19 vaccines via a prism of global health safety. Scientists across the globe, along with companies from both public and private sectors, have predictably arranged cooperative programs to learn about COVID-19, along with taking simultaneous steps on devising vaccine and preparing effective treatments plans. Presently, several clinical trials to approve the efficiency of proposed vaccine solutions have been made successfully. Global health safety concerns on vaccine's efficiency such as high costs of production, provision of vaccine to developing countries, and its influence on the global economy are addressed. This commentary reflects on current efforts related to the development of vaccine against COVID-19, which currently affects the global health status and economy. In addition, the commentary aims at addressing potential risks related to the development of COVID-19 vaccine from the global health safety perspective.

Citing Articles

Prophylactic and therapeutic vaccine development: advancements and challenges.

Weerarathna I, Doelakeh E, Kiwanuka L, Kumar P, Arora S Mol Biomed. 2024; 5(1):57.

PMID: 39527305 PMC: 11554974. DOI: 10.1186/s43556-024-00222-x.


Evaluation of the Most Visible Symptoms Associated with COVID-19 Vaccines Among the Residents of Makkah, Saudi Arabia: An Observational, Cross-Sectional Study.

Qashqari F, Alfelali M, Barasheed O, Almaimani R, Alghamdi A, Alharbi S Infect Drug Resist. 2023; 16:5107-5119.

PMID: 37576522 PMC: 10422958. DOI: 10.2147/IDR.S409200.


A study on the willingness and influencing factors of novel coronavirus vaccination among medical personnel in North China.

Hao J, Liu H, Shi J, Wang Q, Su X, Shi Z Hum Vaccin Immunother. 2022; 18(5):2031775.

PMID: 35377280 PMC: 9196643. DOI: 10.1080/21645515.2022.2031775.


Evaluation of Side Effects Associated with COVID-19 Vaccines in Saudi Arabia.

Alhazmi A, Alamer E, Daws D, Hakami M, Darraj M, Abdelwahab S Vaccines (Basel). 2021; 9(6).

PMID: 34207394 PMC: 8235009. DOI: 10.3390/vaccines9060674.

References
1.
Wang D, Hu B, Hu C, Zhu F, Liu X, Zhang J . Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-1069. PMC: 7042881. DOI: 10.1001/jama.2020.1585. View

2.
Jiang S, Hillyer C, Du L . Neutralizing Antibodies against SARS-CoV-2 and Other Human Coronaviruses. Trends Immunol. 2020; 41(5):355-359. PMC: 7129017. DOI: 10.1016/j.it.2020.03.007. View

3.
Funk C, Laferriere C, Ardakani A . A Snapshot of the Global Race for Vaccines Targeting SARS-CoV-2 and the COVID-19 Pandemic. Front Pharmacol. 2020; 11:937. PMC: 7317023. DOI: 10.3389/fphar.2020.00937. View

4.
Konwarh R . Nanobodies: Prospects of Expanding the Gamut of Neutralizing Antibodies Against the Novel Coronavirus, SARS-CoV-2. Front Immunol. 2020; 11:1531. PMC: 7324746. DOI: 10.3389/fimmu.2020.01531. View

5.
Chojnacky M, Rodriguez A . Effect of thermal ballast loading on temperature stability of domestic refrigerators used for vaccine storage. PLoS One. 2020; 15(7):e0235777. PMC: 7343171. DOI: 10.1371/journal.pone.0235777. View